ImmuRAID-CEA antibody fragment labelled with technetium-99m data

Results of a Phase II trial show that in 33 percent of the 54 patients enrolled, the imaging agent led to detection of new tumors or to decisions that disease was noncancerous. In an additional 18 patients, the technique may have also revealed new diagnostic information that will need to be confirmed during the remaining course of the study. The agent was accurate in diagnosing at least one lesion in 90 percent of the 50 patients with known lung cancer.

Based on the findings, announced at the Bear Stearns Sixth Annual Health Care Conference in New York, IMMU has established the clinical endpoints for a Phase III trial, which will judge the agent's ability to accurately stage lung cancers before surgery. ...